Dyslipidemia is a medical condition characterized by abnormal levels of lipids, including cholesterol and triglycerides, in the blood. It plays a crucial role in the development of cardiovascular diseases, such as atherosclerosis and coronary artery disease. The condition arises when there is an imbalance in the production, utilization, or clearance of lipids, leading to elevated levels of LDL cholesterol, commonly referred to as "bad" cholesterol, and reduced levels of HDL cholesterol, known as "good" cholesterol. Dyslipidemia often results from a combination of genetic factors, lifestyle choices, and underlying health conditions. Poor dietary habits, lack of physical activity, and obesity contribute significantly to its onset. Timely detection and management of dyslipidemia are essential to reduce the risk of cardiovascular events. Lifestyle modifications, including a heart-healthy diet, regular exercise, and smoking cessation, are key components of managing dyslipidemia. In some cases, medications such as statins may be prescribed to help control lipid levels and mitigate cardiovascular risks. Regular monitoring and collaboration with healthcare professionals are crucial for individuals with dyslipidemia to effectively manage and maintain optimal lipid levels, promoting heart health and overall well-being.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India